Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy
- 3 April 2016
- journal article
- research article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 434, 1-8
- https://doi.org/10.1016/j.jim.2016.03.005
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cellsCancer Letters, 2014
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- Critical Appraisal of Four IL-6 ImmunoassaysPLOS ONE, 2012
- Antibody-Based Protein Multiplex Platforms: Technical and Operational ChallengesClinical Chemistry, 2010
- Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine familyInternational Immunopharmacology, 2005
- Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsisCytokine, 2005
- CNTO 328, a monoclonal antibody to IL‐6, inhibits human tumor‐induced cachexia in nude miceInternational Journal of Cancer, 2004
- Serum levels of interleukin‐6 type cytokines and soluble interleukin‐6 receptor in patients with rheumatoid arthritisMediators of Inflammation, 1998
- Interleukin‐6: Structure‐function relationshipsProtein Science, 1997
- The immunochemistry of sandwich ELISAs—I. The binding characteristics of immunoglobulins to monoclonal and polyclonal capture antibodies adsorbed on plastic and their detection by symmetrical and asymmetrical antibody-enzyme conjugatesMolecular Immunology, 1986